Novartis showcases dermatology leadership on International Urticaria Day announcing new data to be presented at EADV 2014 - Seite 2

Novartis specialty dermatology portfolio highlights at EADV 2014 include:

Oral presentations of Xolair's impact on CSU patients' quality of life from the Phase III studies

• Omalizumab reduced symptoms and improved health-related quality of life (HRQoL) in patients with CSU: an analysis from three randomized Phase III trials (abstract FC07; 11 October, 9.45 - 11.15 CET)

• A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CUQ2oL): Is it informative about the response to treatment in CSU patients? (abstract FC07; 11 October, 9.45-11.15 CET) 

Highlights of electronic posters available throughout the EADV congress

• Psoriasis patients with clear or almost clear skin (categorized as Psoriasis Area and Severity Index 90 (PASI 90) to PASI 100) achieved greater health-related quality of life improvements than those with PASI 75 response, according to a sub-analysis of Phase III data
• Secukinumab shows efficacy regardless of baseline disease severity in moderate-to-severe plaque psoriasis patients, according to a pooled analysis of Phase III studies
• Secukinumab 300 mg demonstrated the highest probability of efficacy in clearing skin compared to other biologics currently approved to treat psoriasis, based on a mixed treatment comparison using data from a systematic literature review

Additional secukinumab Phase III analyses at EADV 2014 include data on sustained response, fast relief of disease burden, efficacy (at different treatment stages and in psoriatic arthritis patients), in addition to the further benefit of secukinumab treatment measured by health-related patient quality of life.

Additional analyses of Xolair pivotal Phase III studies include: 

• First demonstration that improvements in urticaria symptoms result in substantial reductions in daytime sleepiness and sleep disturbance
• Pooled analyses of safety data from three pivotal Phase III studies (975 patients) with no new safety signals
• Demonstration that chronic hives, a symptom of CSU, is associated with significant burden across multiple areas of quality of life, greater impairment in work and increased utilization of health resources from the patients' perspective

Novartis-sponsored symposia